Here are five new drug shortages and discontinuations, according to drug supply databases from the FDA and the American Society of Health-System Pharmacists. 

Bumetanide injection: Several manufacturers, including Fresenius Kabi, Hikma Pharmaceuticals, Novadoz Pharmaceuticals and Sagent Pharmaceuticals have reported a shortage of bumetanide injection, a cardiovascular drug used as a loop diuretic. The affected strength is 0.25 milligram/1 milliliter.

Dopamine hydrochloride injection: Hospira has discontinued its dopamine hydrochloride in dextrose 5% injection, a cardiovascular medication used to treat shock and heart failure. The discontinued presentation is 800 milligram/500 milliliter.

Dobutamine hydrochloride injection: Pfizer has discontinued its 12.5 milligram/1 milliliter stren

See Full Page